Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Second eye gets gene therapy in bid to halt blindness

NCT ID NCT06646289

Summary

This study is testing the safety of a gene therapy injection for the second eye in people with X-linked retinitis pigmentosa, an inherited condition that causes vision loss. It is a follow-up for 24 adults and children who previously received the same treatment in their first eye in an earlier trial. The main goal is to see if treating the second eye is safe and if it helps improve or stabilize vision.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for X-LINKED RETINITIS PIGMENTOSA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Massachusetts Eye and Ear Infirmary

    Boston, Massachusetts, 02114, United States

  • Moorfields Eye Hospital

    London, EC1V 2PD, United Kingdom

  • University of Michigan Kellogg Eye Center

    Ann Arbor, Michigan, 48105, United States

Conditions

Explore the condition pages connected to this study.